NASDAQ: TNYATenaya Therapeutics Inc Stock
$4.32+0.03 (+0.7%)
Updated Apr 19, 2024
TNYA Price
$4.32
Fair Value Price
$0.45
Market Cap
$339.19M
52 Week Low
$1.66
52 Week High
$8.09
P/E
-2.57x
P/B
2.43x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$124.08M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.22
Operating Cash Flow
-$102M
Beta
1.87
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TNYA Overview
Tenaya Therapeutics Incorporated is a biotechnology company that develops heart diseases therapies in the U.S. It uses cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic Hypertrophic Cardiomyopathy, and TN-301, a small molecule inhibitor of Histone Deacetylase 6 (HDAC6i) for use in heart gFailure with preserved ejection fraction (HFpEF), as well as genetic Dilated Cardiomyopathy (gDCM). The company was incorporated in 2016 and is headquartered in San Francisco, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TNYA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TNYA ($4.32) is overvalued by 858.46% relative to our estimate of its Fair Value price of $0.45 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TNYA ($4.32) is not significantly undervalued (858.46%) relative to our estimate of its Fair Value price of $0.45 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TNYA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TNYA due diligence checks available for Premium users.
Be the first to know about important TNYA news, forecast changes, insider trades & much more!
TNYA News
Valuation
TNYA fair value
Fair Value of TNYA stock based on Discounted Cash Flow (DCF)
Price
$4.32
Fair Value
$0.45
Overvalued by
858.46%
TNYA ($4.32) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TNYA ($4.32) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TNYA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TNYA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.57x
Industry
15.81x
Market
40.51x
TNYA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.43x
Industry
5.74x
TNYA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TNYA's financial health
Profit margin
Revenue
$0.0
Net Income
-$29.9M
Profit Margin
0%
TNYA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$170.5M
Liabilities
$31.1M
Debt to equity
0.22
TNYA's short-term assets ($111.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TNYA's short-term assets ($111.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TNYA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.9M
Investing
-$14.9M
Financing
$371.0k
TNYA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TNYA vs Biotech Stocks
Tenaya Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.